NYSE: SOLVSolventum

    Solventum Q3 2026 Results: Net Loss $12 Million on Revenue of $1.95 Billion

    • US stocks
    • Earnings
    • Health Care
    A bright hospital operating room with an operating table, ceiling-mounted surgical lights and a wall display
    Yazan.shawahneh, via Wikimedia Commons (CC0). Illustrative image.

    Solventum (NYSE: SOLV) reported third quarter 2026 results, with GAAP revenue of $1.95 billion and a GAAP net loss of $12.0 million, it said on 5 Nov 2026. GAAP diluted EPS was a loss of $0.07 per share. The company's adjusted diluted EPS, a company-defined measure, was $1.45.

    Key highlights

    • Revenue (GAAP): $1.95 billion, down 7.0% YoY and 11.8% QoQ
    • Net income (GAAP): loss of $12.0 million, against $1.27 billion a year earlier
    • Diluted EPS (GAAP): loss of $0.07 per share, against $7.22 a year earlier
    • Adjusted diluted EPS (company-defined): $1.45 per share, down 3.6% YoY

    Summary

    Consolidated (GAAP) $ million
    ParticularsQ3 2026Q3 2025YoYQ2 2026QoQ
    Revenue1,949.02,096.0-7.0%2,209.0-11.8%
    68.01,690.0-96.0%181.0-62.4%
    -12.01,266.0n/a92.0n/a
    Diluted EPS ($)-0.077.22n/a0.53n/a

    Figures are in $ million except EPS; YoY compares with Q3 2025 and QoQ with Q2 2026. Q3 2026 is the three months to 30 Sep 2026, from the company's release. Earlier quarters are checked against the company's SEC XBRL filings. GAAP; net income attributable to the company; diluted EPS. Changes and margins computed by Blacklitt.

    The table shows GAAP revenue of $1.95 billion, down 7.0% from a year earlier and 11.8% from the previous quarter, when revenue was $2.21 billion. GAAP operating income was $68.0 million, against $1.69 billion a year earlier, a fall of 96.0%. The company attributed the lower GAAP operating margin mainly to the prior year's gain on the sale of the Purification and Filtration business and to higher restructuring costs this year.

    GAAP operating margin was 3.5%, against 80.6% a year earlier and 77.1 percentage points lower. Adjusted operating income margin was 19.9%, against 20.6% a year earlier.

    Adjusted figures exclude separation and restructuring costs

    The adjusted diluted EPS of $1.45 is the company's own measure. Its adjusted figures leave out after-tax amortization, restructuring, spin-off and separation costs, certain litigation costs, and acquisition and divestiture-related items. Before tax, the quarter's adjustments to operating income included $157 million of spin-off and separation costs and $50 million of restructuring costs.

    Outlook raised for 2026 adjusted EPS

    The company now expects full-year 2026 adjusted diluted EPS of $7.20 to $7.30, up from a prior range of $7.10 to $7.20. For organic sales growth, the company now points to the upper part of its +2.5% to +3.0% range, and chief executive Bryan Hanson said the business should land near the top of it. It affirmed full-year free cash flow of $200 million to $300 million.

    Excluding about 100 bps of SKU exit impact, the company puts organic growth toward the high end of +3.5% to +4.0%.

    Advanced Wound Care and Health Information Systems grew organically

    Advanced Wound Care net sales were $528 million, up 8.9% reported and 1.5% organically. Health Information Systems net sales were $356 million, up 4.4% organically. Infection Prevention and Surgical Solutions, MedSurg and Dental Solutions declined organically by 5.7%, 2.8% and 7.4%. The company attributes the 2.8% total organic decline to the expected reversal of second-quarter advance orders placed ahead of the ERP system cutover.

    Inference

    Diluted weighted-average shares were 170.8 million in the quarter, against 175.4 million a year earlier. The company spent $403 million on treasury stock purchases in the nine months to 30 Sep 2026. The release does not say whether a dividend was declared, and it gives no full-year GAAP EPS outlook.

    Filed with the US SEC on . Reference: Original filing (SEC)

    Disclaimer:

    The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.

    Figures are from the company's filings with the US Securities and Exchange Commission and are in US dollars. Investing in US stocks from India is subject to the Liberalised Remittance Scheme, currency risk and taxes in both countries.

    Latest posts